New Market Research Report: Zimbabwe Pharmaceuticals & Healthcare Report Q1 2013

Fast Market Research recommends "Zimbabwe Pharmaceuticals & Healthcare Report Q1 2013" from Business Monitor International, now available

by Bill Thompson

(WireNews+Co) - Boston, MA - 04 March 2013

BMI View: The introduction of the pneumococcal conjugate vaccine in Zimbabwe, through a partnership between multiple foreign organisations, has been well received by mothers with young children in Zimbabwe. However, BMI maintains that the market is very unattractive to healthcare sector investors and drugmakers, due to the government's unfulfilled commitments to drive the local pharmaceutical and healthcare industries. This is evidenced by the recent partnership with non-commercial entities. As such, the local pharmaceutical sector is likely to remain neglected and underdeveloped, in turn deterring foreign investment by multinational companies. The country's unstable political situation and poor economic environment contribute to the unattractiveness of the market.

Headline Expenditure Projections

- Pharmaceuticals: US$160mn in 2011 to US$181mn in 2012; +13.3% in local currency and US dollar terms. Forecast largely in line with Q412.
- Healthcare US$824mn] in 2011 to US$919mn in 2012; 11.5% in US dollar terms. Forecast unchanged from Q412.
- Medical devices: US$44mn in 2011 to US$49mn in 2012; +12.1% in US dollar terms. Forecast unchanged from Q412.

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/541306_zimbabwe_pharmaceuticals_healthcare_report_q1.aspx?afid=201) (http://www.fastmr.com/prod/541306_zimbabwe_pharmaceuticals_healthcare_report_q1.aspx?afid=201)

Risk/Reward Rating: In BMI's Pharmaceutical Risk/Rewards Ratings (RRRs) table for Q113, Zimbabwe's score is an unchanged 30.1, which again ranks the country 28th of the 30 markets surveyed in the Middle East and Africa (MEA). Zimbabwe will remain one of the least attractive pharmaceutical and healthcare markets regionally and globally (currently ranking 92nd out of 95 countries surveyed) on account of the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.

Key Trends And Developments

- In September 2012, New Ziana reported that many Indian companies are looking to invest in Zimbabwe's pharmaceutical industry. Owen Mugurungi, the director of the AIDS and tuberculosis unit at the Ministry of Health, Children and Welfare was quoted as saying that several investors are willing to collaborate with the government to set up plants to produce generic antiretroviral (ARV) drugs. However, we caution that wider operating conditions may put a stop to such activities.
- Zimbabwean private hospitals have raised their fees by 20%, which is expected to result in an increase in premiums paid by patients to medical aid societies. The hospitals increased their fees following a resolution by the Private Hospitals Association of Zimbabwe (PHAZ) in August 2012, according to statements made by PHAZ vice chair Margaret Maulana to News Day. However, several companies and their employees will not be able to meet the increase in private hospital fees, as the industry is already struggling, an executive from one of the medical aid societies said. We expect this to exacerbate the already significant problems in the country's healthcare system.
-

Fast Market Research (http://www.fastmr.com?afid=201) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget.  For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.